Navigation Links
Antineoplastic agents associated with thyroid dysfunction
Date:10/18/2011

Antineoplastic agents such as immunotherapies and targeted therapies that specifically target signaling pathways in cancer cells are associated with thyroid dysfunction in 20%-50% of cancer patients taking them, which can adversely affect patients' quality of life, according to a study published Oct. 18 in the Journal of the National Cancer Institute.

Over the past two decades, novel antineoplastic agents have been introduced that inhibit specific cellular processes to limit cancer cell growth. Some of these agents cause thyroid dysfunction, which physicians often overlook because of the complexity of the clinical picture in cancer patients. The symptoms of thyroid dysfunction, such as fatigue, weakness, depression, memory loss, and cardiovascular effects can be wrongly attributed to the primary disease. If under-diagnosed, thyroid dysfunction can adversely affect a patient's quality of life.

To understand the thyroid-related side effects of antineoplastic agents, their frequency, and underlying mechanisms, Ole-Petter Riksfjord Hamnvik, M.D., of the Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women's Hospital in Boston, and colleagues reviewed articles on thyroid dysfunction in cancer patients. The researchers found that there are no known strategies to prevent thyroid disease in patients receiving these new antineoplastic agents, and that possible preventative measures may be more toxic than the thyroid disease itself. They also say that screening for thyroid disease is likely beneficial, but note that there were no screening recommendations for asymptomatic patients in the literature they reviewed. However, in this review, the authors provide their own recommendations for patients based on the pattern of abnormalities with each agent, in addition to recommending the monitoring of thyroid function tests in clinical trials of antineoplastic agents.

The researchers also recommend several paths of research that should be pursued, namely knowledge of the biological effects of the antineoplastic agents on the thyroid, so they can identify possible preventative strategies and improve the proposed screening strategies. They also recommend performing large randomized clinical trials of screening and treatment of thyroid disease to evaluate the improvements in patient quality of life and fatigue as well as to evaluate the unanticipated effects of cancer outcomes.

The researchers write, "Treatment for thyroid diseases is safe and likely to enhance patient quality of life, as well as potentially allow effective treatments for the underlying cancer to continue."

They note however, that there are many levels of uncertainty and that most of the data are derived from case reports or case series, small prospective studies, or laboratory-based studies. They recommend close monitoring of patients receiving these antineoplastic agents. "This may allow early recognition and treatment of thyroid disease, allowing continued treatment of the underlying cancer, as well as improving the quality of life of the patient."


'/>"/>

Contact: Zack Rathner
jncimedia@oxfordjournals.org
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Professional Insurance Agents to Hold 2010 Federal Legislative Summit March 17-18
2. Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth
3. Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year
4. Health Insurance Agents Work with Zane Benefits to Offer New Solutions amid Health Care Reform
5. Mayo-led research team develop agents that keep insulin working longer
6. Study provides molecular rationale for combining targeted agents to treat breast cancer
7. VCU Massey first to combine targeted agents to kill multiple myeloma cells
8. Improved protocols for contrast agents eliminates new cases of nephrogenic systemic fibrosis
9. Turning agents of disease into tools for health and better living
10. New anti-cancer agents show promise for treating aggressive breast cancers
11. Imaging agents offer new view of inflammation, cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology: